The study concluded that patients receiving combination therapy (anti-TNF-a and thiopurine) are at an increased risk of developing T cell NHL compared with the less significant increased risk from thiopurine monotherapy, but TNF-a inhibitor monotherapy did not affect patient risk [21]. This evidence concerns the gene TNF and T-cell non-Hodgkin lymphoma.